Amgen (AMGN) PT Raised to $202 at BMO Capital Amid Positive Repatha Data
Tweet Send to a Friend
BMO Capital raised its price target on Amgen (NASDAQ: AMGN) to $202.00 (from $197.00) while maintaining a Outperform rating following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


